The endothelial cell is the essential cell type forming the inner layer of the vasculature. Two families of receptor tyrosine kinases (RTKs) are almost completely endothelial cell specific: the vascular endothelial growth factor (VEGF) receptors (VEGFR1-3) and the Tie receptors (Tie1 and Tie2). Both are key players governing the generation of blood and lymphatic vessels during embryonic development. Because the growth of new blood and lymphatic vessels (or the lack thereof ) is a central element in many diseases, the VEGF and the Tie receptors provide attractive therapeutic targets in various diseases. Indeed, several drugs directed to these RTK signaling pathways are already on the market, whereas many are in clinical trials. Here we review the VEGFR and Tie families, their involvement in developmental and pathological angiogenesis, and the different possibilities for targeting them to either block or enhance angiogenesis and lymphangiogenesis.
B
lood and lymph are the two major bodily fluids that transport and distribute, via the blood and lymphatic vessels, molecules and cells throughout the body. The essential building blocks of all vessels are endothelial cells (ECs). In the smallest vessels (capillaries), the vascular wall consists almost exclusively of ECs, whereas in larger vessels, and in particular the arteries, the vascular wall is multilayered, with the ECs forming the innermost layer (endothelium or the intimal layer). This is followed by a layer of smooth muscle/mural cells embedded in elastic connective tissue (media) and by the outer adventitial layer, which consists mainly of connective tissue (Boulpaep 2009 ). The growth of new blood vessels in the initially avascular embryo occurs via vasculogenesis, in which precursor cells from the mesoderm (hemangioblasts) aggregate and differentiate. In the yolk sac, cells in the periphery of the blood islands become ECs, whereas cells in the center differentiate into blood cells. A primitive vascular network is then established via sprouting angiogenesis (the growth of new blood vessels from pre-existing vessels) and extensive remodeling (Lugus et al. 2005) . The contribution of vasculogenesis in the development of the lymphatic system has so far been shown only in birds (Papoutsi et al. 2001) and frogs (Ny et al. 2005) , whereas in mammals, the lymphatic system may arise predominantly by a lymphangiogenic sprouting process that starts from the large veins (Wigle and Oliver 1999) .
Vasculogenesis is largely restricted to early embryonic development, and angiogenesis is the major mechanism of vascular growth in later embryogenesis and in the adult. When new vessels start to grow, the ECs execute a complex program. They have to switch from their quiescent, immotile state into a proliferating, migrating state. A major trigger for this switch is hypoxia (insufficient oxygen concentration), which is often created by tissue expansion. An oxygensensing transcriptional system activates a genetic regulatory master switch, which engages the angiogenesis machinery.
Two RTK families-the VEGF receptors (VEGFRs) and the Tie receptors ( Fig. 1 )-are largely restricted to the ECs in vertebrates, although they also are expressed in a few other cell types, notably in some hematopoietic cells (listed in the supplementary information S2 in Olsson et al. 2006) . From the three VEGFRs, only two (VEGFR-2 and VEGFR-3) drive angiogenesis, whereas VEGFR-1 mostly acts to restrict the angiogenic response (Ho et al. 2012) and to recruit macrophages for tissue remodeling (Pipp et al. 2003) . Under normal conditions, stimulation of VEGFR-2 results in angiogenesis of blood vascular ECs (BECs), whereas stimulation of VEGFR-3 elicits a similar response in lymphatic ECs (LECs). The Tie receptors have context-dependent roles in EC survival and in the stabilization and remodeling of blood and lymphatic vessels.
Two other RTK families play important roles in angiogenesis, namely the platelet-derived growth factor (PDGF) receptors and Eph receptors. The PDGF receptors are important for the stabilization of the vascular wall by mural cells, such as pericytes and smooth muscle cells (Andrae et al. 2008) , and the Eph receptors are involved in determining arterial versus venous identity (Adams and Eichmann 2010) . ECs normally do not express PDGF receptors, and the Eph receptors and their membrane-bound ligands (ephrins) are not exclusively expressed by endothelial cells. This paper will focus on the relatively EC-specific VEGF and Tie receptors.
Blood versus Lymphatic Vasculature
The cardiovascular system is a high-pressure system from which blood plasma continuously leaks out into tissues. The primary function of the lymphatic vessels is to drain this fluid and to return it into the blood circulation. On its path, the lymph, including its cellular elements, passes through one or several lymph nodes where it is scanned for foreign antigens; hence, the lymphatic system is essential for an efficient immune defense. In the intestine, lymphatic vessels serve yet another specialized function. They absorb long chain dietary triglycerides and other lipophilic compounds after their digestion and transport these in the form of chylomicrons to other parts of the body. The blood and lymphatic vessels are also structurally different; with the exception of fenestrated and discontinuous endothelia, BECs connect to each other via both tight and adherens junctions and form a continuous basement membrane on their abluminal side. LECs, on the other hand, are only loosely connected to each other and have a discontinuous basement membrane, relying on so-called anchoring filaments to connect to the pericellular matrix (Jeltsch et al. 2003) .
Several molecular markers differ between BECs and LECs. Although both BECs and LECs carry panendothelial markers, such as plateletendothelial cell adhesion molecules (PECAM-1), they express different subsets of RTKs. VEGFR-1 and VEGFR-2 are expressed by BECs, whereas VEGFR-2 and VEGFR-3 are expressed by LECs. However, VEGFR-3 is also expressed in discontinuous or fenestrated blood vascular endothelium (Partanen et al. 2000) . Also the high endothelial venules (HEVs) that carry out important immune functions (Kaipainen et al. 1995; Lacorre et al. 2004 ) and the abnormal vasculature of tumors can express VEGFR-3 (Tammela et al. 2008 ).
Tip and Stalk Cells Express Different RTKs
Some of the mechanisms of vessel sprouting in angiogenesis and lymphangiogenesis are surprisingly similar to neuronal axon guidance and the formation of the tracheal system in the fruit fly. The cell leading the EC migration toward a chemotactic stimulus, called the tip cell, sends out numerous filopodia in order to integrate attractive and repellent signals. Repulsive signals are mediated, for example, by the EphB4 RTK and its transmembrane ephrinB2 ligand; these inhibit the direct interaction between arterial and venous endothelial cells (Füller et al. 2003) . Such behavior is analogous to functioning of the growth cones of nerve cells. Migration signals are mediated via VEGFR-2 and VEGFR-3 expressed by the tip cells. The Notch ligand Dll4 in the tip cells mediates lateral inhibition of sprouting to the adjacent cells (stalk cells) via Notch signaling. This in turn induces up-regulation of VEGFR-1 and down-regulation of both VEGFR-2 and VEGFR-3 in the stalk cells (Fig. 2 ) (Jakobsson et al. 2009 ). Tip cells also express neuropilin-1, which appears essential for the tip cell functions. Neuropilin-1 acts as a coreceptor for VEGFR-2 and neuropilin-2 acts as a coreceptor for both VEGFR-2 and VEGFR-3 (Favier et al. 2006; Karpanen et al. 2006; Pan et al. 2007; Caunt et al. 2008; Xu et al. 2010) . In order to achieve directed, hierarchical sprouting, a VEGF-A gradient is established around the cells producing VEGF-A. Different VEGF-A isoforms vary in their gradient-forming ability due to their different affinities to heparan sulfate proteoglycans on the cell surface and in the pericellular matrix (Ruhrberg et al. 2002) . Eventually, tip cells need to detect and connect to neighboring sprouts to form perfused loops. This process is regulated by neuropilin signaling and macrophages that accompany angiogenic processes (Gerhardt et al. 2004; Fantin et al. 2010 ).
MOLECULAR MECHANISMS OF ANGIOGENESIS VEGF Receptors and Their Ligands
The ligands of the VEGFRs, the mammalian vascular endothelial growth factors (VEGF- Figure 1 . Schematic presentation of Tie and VEGF receptors and their ligands. There are five VEGFs and three angiopoietins in mammals (the mouse ortholog of Ang4 is also referred to as Ang3). Dotted lines indicate that the ligand -receptor interaction is weak or nonexistent for some isoforms of the ligand (Joukov et al. 1997; Baldwin et al. 2001; Leppanen et al. 2011) . CUB, Clr/Cls, urchin EGF-like protein, and bone morphogenetic protein I; CF, coagulation factor; MAM, meprin/A5-protein/PTPm; Ig, immunoglobulin; EGF, epidermal growth factor; FN, fibronectin.
A, VEGF-B, VEGF-C, VEGF-D, and placenta growth factor [PlGF]) ( Fig. 1) are crucial regulators of angiogenesis. Their activities are modulated through binding to the heparan sulfate proteoglycan and neuropilin coreceptors. VEGFRs are type-V RTKs comprising a family of transmembrane receptors with an extracellular part of seven immunoglobulin (Ig) homology domains (Fig. 1) . VEGFRs utilize distinct Ig homology domains for ligand binding and dimerization. The VEGF family members are antiparallel homodimeric, secreted glycoproteins with multiple isoforms that are generated by alternative splicing and posttranslational processing. Characteristic for the VEGFRs and for most other RTKs is the dimerization of the extracellular domains upon ligand binding. The interactions of the membrane-proximal domains ensure correct positioning of the intracellular domains resulting in their autophosphorylation and downstream signaling (Koch et al. 2011) . VEGFR-2 and VEGFR-3 contribute to Erk1,2 activation, whereas Akt activation is mostly induced by VEGFR-3 (Tvorogov et al. 2010; Koch et al. 2011) .
Ligand binding to VEGFR-2 induces a robust tyrosine phosphorylation and results in a strong angiogenesis response (Waltenberger et al. 1994) , whereas VEGFR-1 has only weak tyrosine kinase activity and seems to modulate angiogenesis as a decoy receptor (Ferrara 2004; Shibuya and Claesson-Welsh 2006; Ho et al. 2012) . VEGF-A is a ligand for both VEGFR-2 and VEGFR-1, whereas VEGF-B and PlGF are VEGFR-1-specific ligands. Alternative splicing of both VEGFR-1 and VEGFR-2 gives rise to secreted receptor variants, which are able to bind their respective ligands and may inhibit angiogenesis and lymphangiogenesis (Kendall and Thomas 1993; Albuquerque et al. 2009 ).
VEGFR-3 and its primary ligand VEGF-C play important roles in the formation of the lymphatic vascular system (Tammela and Alitalo 2010) . Upon removal of the propeptides, the VEGFR-3 ligands VEGF-C and VEGF-D acquire a strong binding affinity also for VEGFR-2 and become angiogenic (Joukov et al. 1997; Stacker et al. 1999; Anisimov et al. 2009; Leppanen et al. 2011) . VEGF-C activation of VEGFR-3 and ligand-induced VEGFR-3/ VEGFR-2 heterodimers are also important in sprouting angiogenesis (Tammela et al. 2008; Nilsson et al. 2010) . Furthermore, VEGF-C-induced VEGFR-3 activation contributes to the phenotypic conversion of endothelial cells at fusion points of vessel sprouts (Tammela et al. 2011b ).
Tie Receptors and Their Ligands
In addition to the VEGF-VEGFR system, the angiopoietin -Tie system is the second endothelial-specific RTK pathway involved in blood and lymphatic vessel development. The intracellular Fig. 1) (Barton et al. 2006; Macdonald et al. 2006) . The angiopoietin growth factors (Ang1, Ang2, and Ang4) (Fig. 1 ) function as ligands for Tie2 Maisonpierre et al. 1997; Kim et al. 1999; Valenzuela et al. 1999; Lee et al. 2004) . The angiopoietins comprise a structurally unique family of growth factor ligands that multimerize to form various-sized multimers with multiple receptor-binding domains (Kim et al. 2005) . The angiopoietins do not directly bind to Tie1, and therefore Tie1 is considered an orphan receptor. However, Ang1 and Ang4 activate Tie1 in heteromeric receptor complexes in endothelial cells, which most likely involve the interaction between Tie1 and Tie2 (Saharinen et al. 2005; Seegar et al. 2010) .
Activation of Tie2 occurs via a unique mechanism, which is not used by other soluble growth factor ligands, and thus differs from, for example, VEGF-induced receptor activation (Fukuhara et al. 2008; Saharinen et al. 2008) . When contacting ECs are stimulated with angiopoietins, the Tie2 receptors are rapidly translocated to EC -EC junctions to form homomeric Tie2 complexes that associate in trans across the EC-EC junctions ( Fig. 2) (Fukuhara et al. 2008; Saharinenetal.2008) .Tie1isassociatedwithTie2 and traffics also to these complexes (Saharinen et al. 2008 ). The junctional Ang1-Tie2 complexes activate preferentially the phosphatidyl-inositol-3 kinase (PI3K)/Akt kinase pathway to promote cell survival, EC stability, and barrier function (Fukuhara et al. 2008; Saharinen et al. 2008) . The junctional Tie2 complexes are likely activated in the quiescent vasculature. In mobile ECs, matrix-bound Ang1 activates Tie2 in ECmatrix contacts to induce EC-matrix adhesion and cell migration via activation of the extracellular regulated kinases (Erk) (Fukuhara et al. 2008 ) and the adaptor protein DokR (Saharinen et al. 2008 ).
Ang2 stimulation of ECs results in Tie2 translocation to EC -EC junctions, but, whereas Ang1 induces Tie2 activation, Ang2 induces only weak Tie2 tyrosine phosphorylation (Maisonpierre et al. 1997; Saharinen et al. 2008 ). Thus, Ang2 in some conditions acts as an antagonist to inhibit the more robust Ang1-induced Tie2 activation. Ang2 is stored in endothelial cell Weibel-Palade bodies, from where it is rapidly released in response to various stimuli (Fiedler et al. 2004 ). Ang2 levels are increased in tumor patients and in numerous diseases characterized by vascular leakage and inflammation, for example, in sepsis (Parikh et al. 2006 ). In the latter situations, Ang2 may compete with Ang1 in Tie2 binding, promoting EC destabilization and vessel regression. In tumors, Ang2 promotes angiogenesis and vascular sprouting, possibly acting as a Tie2 agonist (Holash et al. 1999; Hashizume et al. 2010; Daly et al. 2013) .
Angiopoietins may also directly bind to integrins, and this may regulate the functions of tip cells, which express high levels of Ang2 but low Tie2 levels Felcht et al. 2012) . The Tie2 receptor also interacts with integrins when endothelial cells adhere on fibronectin, sensitizing cells for Ang1 signaling (Cascone et al. 2005) . Ang2 regulates Tie2 localization in an integrin-dependent manner (Pietila et al. 2012) , and induces clustering of Tie2 and b3 integrins in cell-cell junctions stimulating integrin turnover (Thomas et al. 2010 ).
Endothelial Cell-Specific RTKs in Development

VEGF Receptors
VEGFR-2 is expressed in the early mesoderm in cells that undergo angioblast differentiation, and mice lacking VEGFR-2 die at embryonic day E8.5-9.5 as a result of defects in the development of hematopoietic and endothelial cells (Quinn et al. 1993; Shalaby et al. 1995) . Mice lacking a single VEGF-A allele display abnormal blood vessel development and embryonic lethality before E9.5 (Carmeliet et al. 1996; Ferrara et al. 1996) . VEGF-A and VEGFR-2 expression decrease postnatally, but expression is again up-regulated in tissues undergoing physiological or pathological angiogenesis (Ferrara 2004) . In hypoxic cells, VEGF-A expression is up-regulated via the oxygen sensor system that works via the hypoxia-inducible transcription factor (HIF) (Germain et al. 2010) .
Deletion of VEGFR-1 from mouse embryos results in a severely disorganized vasculature, which results from an increased commitment of mesenchymal precursor cells to the hemangioblast lineage (Fong et al. 1995 (Fong et al. , 1999 . Similarly, VEGFR-1 deletion in adult vessels leads to increased angiogenesis (Ho et al. 2012) . However, deletion of the tyrosine kinase domain of VEGFR-1 does not affect vascular development (Hiratsuka et al. 1998) , nor does the deletion of its specific ligands VEGF-B or PlGF compromise mouse viability or lead to significant phenotypes in physiological conditions (Bellomo et al. 2000; Carmeliet et al. 2001 ). This has led to the view that VEGFR-1 and its soluble isoform (sVEGFR-1) act primarily by sequestering excess VEGF-A from its major receptor VEGFR-2 modulating endothelial cell proliferation (Kearney et al. 2002) and sprout formation (Chappell et al. 2009 ).
During early embryonic development, VEGFR-3 is expressed widely in the ECs but thereafter it becomes gradually restricted to the developing lymphatic vessels (Kaipainen et al. 1995) . VEGFR-3-deficient mice die at E9.5 due to defective remodeling and maturation of blood vessels prior to the development of lymphatic vessels (Dumont et al. 1998) . VEGF-Cdeficient mice die about 3 days later due to edema upon failure of the lymphatic vessel development . In contrast, the lymphatic vascular development is not affected in VEGF-D-deficient mice (Baldwin et al. 2005) . Strikingly, loss of both VEGFR-3 ligands, VEGF-C and VEGF-D, fails to reproduce the early embryonic lethality of VEGFR-3-deficient mice (Haiko et al. 2008) . One explanation for this may be that the VEGFR-3-matrix/integrin interactions are sufficient for the early embryonic development (Zhang et al. 2005; Galvagni et al. 2010 ). In addition, the collagen and calcium-binding EGF domains 1 protein (CCBE1) enhances VEGF-C-induced lymphangiogenesis and is also important for lymphatic vascular development Bos et al. 2011; Hagerling et al. 2013 ).
The Ang/Tie System
The Ang-Tie system is required for the remodeling of the developing blood and lymphatic vasculatures after their initial assembly regulated by the VEGFs ).
Tie2 2/2 mouse embryos show severely impaired cardiac development, hemorrhages, and reduced numbers of endothelial cells, resulting in the death of the embryos by E10.5 (Dumont et al. 1994 ). The gene-targeted embryos deficient of the Tie2 ligand Ang1 have a very similar phenotype, including impaired cardiac development and defective remodeling of the primary vascular plexus, resulting in embryonic lethality (Suri et al. 1996) . In addition, the ECs of the Ang1 2/2 embryos are rounded and poorly associated with basement membranes. Ang1 is dispensable in the adult vasculature during normal homeostasis, but it is required to limit angiogenesis in pathological processes. Conditionally, Ang1-targeted mice develop excessive tissue fibrosis upon vascular stress, suggesting that Ang1 limits perivascular fibrosis, perhaps counteracting TGF-b signaling (Jeansson et al. 2011) .
The Tie1 2/2 mouse embryos have impaired endothelial integrity and hemorrhages, resulting in lethality starting around E13.5, and the deletion of both Tie1 and Tie2 results in a similar, but more severe phenotype than that of the Tie2 2/2 embryos (Puri et al. 1995; Sato et al. 1995) . Embryos chimeric for the gene-targeted Tie1 and Tie2 alleles showed that Tie1 and Tie2 are cellautonomously required for EC survival in the microvasculature during late embryogenesis and in essentially all blood vessels in the adult (Partanen et al. 1996; Puri et al. 1999) . Tie1 is also critical for lymphatic development; the jugular lymph sacs of Tie1 2/2 mouse embryos appear malformed, and the embryos are swollen, before any signs of blood vascular defects (D'Amico et al. 2010; Qu et al. 2010) .
The Ang2 2/2 mice die postnatally or, depending on the background, survive until adulthood. The surviving Ang2 2/2 mice accumulate chylous ascites due to malfunctioning lymphatic vessels, which are abnormally attached to the smooth muscle cells (Gale et al. 2002; Dellinger et al. 2008) . The blood vascular defects of Ang2 2/2 mice are limited to the vitreous vessels. However, ectopic overexpression of Ang2 in developing mouse embryos results in embryonic lethality and a vascular phenotype similar to that of Ang1 2/2 embryos, suggesting that at least in certain circumstances Ang2 may act as an antagonist of Ang1 (Maisonpierre et al. 1997 ) despite being an agonist of Tie2 in others (Daly et al. 2013 ).
ANGIOGENESIS IN DISEASE
The endothelial cells of healthy adult organisms are largely quiescent. Notable exceptions-accompanied by local increases in VEGF-A and VEGF-A receptor expression-include wound healing and tissue repair (Tonnesen et al. 2000) , exercise-induced angiogenesis in the heart and skeletal muscle (Prior et al. 2004) , the hair cycle (Yano et al. 2001) , and, in the female, reproductive cycle and placenta development (Augustin 2005) . Pathological angiogenesis differs from physiological angiogenesis, which is tightly controlled and spatially and temporally limited. Pathological angiogenesis plays an important role in many diseases, notably in tumor development.
Angiogenesis and Tumor Development
Tumor Angiogenesis and Tumor Lymphangiogenesis
The concept that tumors are angiogenesis dependent has led to multiple attempts of therapeutic intervention. In several tumor models, the initial stages of tumor growth occur without the involvement of blood vessels until oxygen diffusion becomes limiting and the hypoxic tumor cells start to stimulate vessel growth. This event is called the "angiogenic switch" and it can occur already in the premalignant stages of tumor development (Hanahan et al. 1996; Baeriswyl and Christofori 2009) .
VEGF-A/VEGFR-2 is the major growth factor axis involved in tumor angiogenesis (Ferrara et al. 2007 ). The role of VEGF-A in tumor angiogenesis was validated by experiments showing that angiogenesis in tumors and, subsequently, tumor growth could be inhibited by VEGF-A-blocking antibody therapy (Kim et al. 1993) . The anti-VEGF-A monoclonal antibody Bevacizumab (Avastin) was the first antiangiogenic cancer drug targeting this axis. However, not all tumors are sensitive to antiangiogenic therapy (intrinsic resistance), and most sensitive tumors will eventually become resistant (evasive resistance) (Abdullah and Perez-Soler 2011; Sennino and McDonald 2012; Singh and Ferrara 2012) . A tumor could competitively circumvent VEGF-A inhibition by increasing its VEGF-A production or by switching to an alternative ligand or receptor. For example, VEGFR-3, which is expressed in the tumor vasculature, can be activated by VEGF-C or VEGF-D and after their proteolytic processing, these factors can additionally activate VEGFR-2 (Tammela et al. 2008; Anisimov et al. 2009 ). Whether PlGF can drive tumor angiogenesis has been controversial, also due to the fact that the PlGF receptor VEGFR-1 appears to be a negative regulator of angiogenesis (Bais et al. 2010; Van de Veire et al. 2010) . However, VEGFR-1 is expressed in certain tumor types, and in a fraction of mononuclear phagocytes that contribute other signals for tumor angiogenesis (Bais et al. 2010) . Additional mechanisms of resistance to VEGF-A blocking include vessel co-option (Huang et al. 2009 ), recruitment of myeloid cells from the bone marrow (Ferrara 2010) , and other angiogenic factors, such as fibroblast growth factors (FGFs) (Nissen et al. 2007 ). Targeting multiple angiogenic pathways may lead to improved efficacy of antiangiogenic therapy.
Tumor vasculature is far from normal; it is very heterogeneous and leaky, and shows a lack of hierarchical organization. Hence, blood flow is slow and the interstitial pressure inside the tumor is high, making it difficult for cytostatic drugs to reach their target cells. The current antiangiogenic drugs reduce tumor blood vessels, resulting in the "normalization" of the remaining vasculature, with less vascular leakiness, and improved pericyte coating and blood flow (Jain 2005) .
The angiopoietin-Tie system is also involved in tumor vascularization (see section on Targeting Angiopoietin Signaling). Ang1 has been implicated in the process of tumor vessel normalization during VEGFor Ang2-blocking therapies in mouse models (Winkler et al. 2004; Falcon et al. 2009) , whereas Ang2 appears to directly stimulate tumor vascularization. Ang2 is thought to destabilize tumor co-opted blood vessels, resulting in hypoxia and enhanced VEGF-A expression, and the initiation of a neoangiogenic switch (Holash et al. 1999 ). Ang2 also stimulates sprouting angiogenesis together with VEGF-A (Hashizume et al. 2010 ).
Hematogenous and Lymphatic Metastasis
Tumors can metastasize via the blood vessels (hematogenous metastasis) or the lymphatic vessels (lymphatic metastasis). Tumor vascularization correlates with hematogenous metastasis (Weidner et al. 1991; Graeber et al. 1996) and VEGF-A or VEGFR-2 have provided prognostic markers for metastasis in some studies (Bremnes et al. 2006) . VEGF-C and VEGF-D stimulate intratumoral and tumor-associated lymphangiogenesis and lymphatic metastasis (Stacker et al. 2002; He et al. 2004; Alitalo 2011) . Intratumoral lymphatic vessels are rare and mostly nonfunctional, but they can be detected in several human tumors and at least in some studies their number correlated with VEGF-C and VEGF-D expression and clinical outcome . Most of the tumor-associated lymphatic vessels develop in the tumor periphery; they are recruited from the surrounding lymphatic vasculature He et al. 2004 He et al. , 2005 , and facilitate tumor dissemination via the lymphatic vessels. Furthermore, VEGF-A and VEGF-C both promote collecting lymph vessel enlargement, increased lymph flow, lymph node lymphangiogenesis, and lymphatic metastasis (He et al. 2002; Roberts et al. 2006; Tammela et al. 2011a) .
Recently, Ang2 was shown to increase tumor lymphangiogenesis (Holopainen et al. 2012) , as well as metastasis to lymph nodes and distant organs, and its blocking using antibodies inhibited the metastasis (Holopainen et al. 2012 ). The mechanisms likely involve tumor-associated Tie2-expressing macrophages (TEMs) (Mazzieri et al. 2011) , and direct effects on endothelial integrity (Holopainen et al. 2012 ).
Insufficient Angiogenesis in Ischemia
Angiogenesis is one of the hallmarks of malignant tumors and an etiological agent in diseases such as diabetic retinopathy and age-related macular degeneration (AMD). On the other hand, chronic ischemic diseases are characterized by a surprising absence or insufficiency of the angiogenic response to local hypoxia. For example, in coronary artery disease, the formation of new collateral blood vessels to bypass the sclerotic arteries would obviously be beneficial for the patient; however, this process, arteriogenesis, and angiogenesis appear insufficient in most of such cases.
Several trials have attempted to stimulate collateral vessel growth and repair (Zachary and Morgan 2011) . The most straightforward approach has been to apply growth factors that directly activate VEGFRs and thus stimulate EC proliferation. Early on, clinical trials appeared to demonstrate the beneficial effect of both VEGF-A and VEGF-C therapy in cardiovascular disease. However, this strategy to improve cardiovascular function has not been translated into clinical practice (Losordo et al. 2002; Reilly et al. 2005; Stewart et al. 2009; Vuorio et al. 2012 ). The VEGFR-1 ligands PlGF and VEGF-B have both been proposed to play important roles during ischemic revascularization, especially in the heart. In mice, PlGF deletion impaired angiogenesis during ischemia (Carmeliet et al. 2001; Luttun et al. 2002) . VEGF-B-stimulated coronary artery growth in transgenic rats (Bry et al. 2010) , and deletion of VEGF-B in mice resulted in reduced heart size and vascular dysfunction after transient coronary occlusion as well as impaired recovery from experimentally induced myocardial ischemia (Bellomo et al. 2000; Li et al. 2008b ) and VEGF-B-stimulated coronary artery growth in transgenic rats (Bry et al. 2010) .
It is possible that other growth factor and cytokine signals are required in addition to VEGF signals to achieve significant therapeutic angiogenesis. Supporting this concept, a designed VEGF-angiopoietin growth factor chimera was superior to VEGF in inducing therapeutic angiogenesis with improved perfusion and less leakage in a mouse model of limb ischemia (Anisimov et al. 2013 ). On the other hand, the failures could be due to shortcomings in study design or technology (Ylä-Herttuala 2009). In order to activate a multiplicity of proangiogenic stimuli, gene therapy with upstream angiogenic master switches, such as HIF, has been proposed ).
Lack of Lymphangiogenesis in Lymphedema
Lymphedema (insufficient lymphatic drainage) may be caused by deficient lymphangiogenesis, or lymphatic valve deficiency (Alitalo 2011; Norrmén et al. 2011) . A relatively common cause of type-I hereditary lymphedema (Milroy disease) is lymphatic vessel hypoplasia due to decreased signaling by a VEGFR-3 allele having a missense point mutation inactivating the kinase domain (Karkkainen et al. 2000) . Interestingly, although all ECs carry the mutant allele, it mostly affects the peripheral lymphatic capillaries, which are severely hypoplastic or absent (Bollinger et al. 1983 ). In one pedigree, a mutation in the coding region of the VEGF-C gene has been shown to cosegregate with the lymphedema phenotype (Gordon et al. 2013) . Another rare cause of lymphedema is a mutation in the CCBE1 gene (Alders et al. 2009 ), which results in compromised VEGF-C-induced lymphangiogenesis Bos et al. 2011) . A somewhat similar phenotype is observed in mice when VEGFR-3 signaling is inhibited (Makinen et al. 2001) . However, therapeutic dosing of VEGF-C resulted in sufficient activation of VEGFR-3 and rescued the disease phenotype in mice . Treating lymphedema by activating the primarily lymphangiogenic VEGF-C/VEGFR-3 axis has been also proposed as a rational therapy for secondary lymphedema, which is commonly caused by lymphatic vessel damage by surgery, infectious diseases, or traumas (Tammela et al. 2007; Alitalo 2011) .
Role of Ang2 Signals in Inflammation
Tissue inflammation commonly stimulates angiogenesis and lymphangiogenesis. Blood and lymphatic vessels are conduits for immune cell trafficking and, when activated, the inflammatory cells produce a plethora of cytokines, including VEGFs, proteases, and growth factors that directly act on ECs promoting vascular permeability and angiogenesis. Not surprisingly, angiogenesis and often also lymphangiogenesis characterize a variety of chronic inflammatory diseases (e.g., rheumatoid arthritis, psoriasis, and some autoimmune and other disorders with inflammatory features such as obesity and diabetic retinopathy) (Costa et al. 2007; Alitalo 2011) . Although angiogenesis is not the underlying cause in these disorders, antiangiogenic intervention could prove beneficial.
Ang2 is locally released from the secretory storage granules at sites of endothelial activation, and it acts as a proinflammatory molecule by sensitizing the endothelium, for example, to the tumor necrosis factor-a-induced expression of endothelial cell adhesion molecules (Fiedler et al. 2006) . In a mouse model of chronic airway inflammation, Ang2-blocking agents decreased the remodeling of mucosal capillaries into venules, the amount of leukocyte influx, and disease severity (Tabruyn et al. 2010) .
In the pathogenesis of diabetic retinopathy, Ang2 is up-regulated in the endothelium and seems to induce the loss of pericytes from the retinal vasculature. Reducing the Ang2 levels inhibited diabetes-induced pericyte loss and decreased the number of acellular capillary segments (Hammes et al. 2004 ).
Ang2 may also directly act on endothelial cell-cell junctions to promote vascular leakage. The levels of Ang2 increase in a number of human diseases associated with inflammation and characterized by microvascular leakage, including sepsis and the acute respiratory distress syndrome. Notably, Ang2 induction precedes and contributes to the adverse outcomes in sepsis, suggesting that it is possible to target Ang2 in this condition (Parikh et al. 2006; David et al. 2012) . In murine models, Ang1 has beneficial effects on alleviating vascular dysfunction, and some of the effects of Ang1 are likely mediated via its ability to reduce vessel permeability by reducing gaps between the ECs (Baffert et al. 2006; Li et al. 2008a) . Furthermore, Ang1 also inhibits excessive angiogenesis, and pathological tissue fibrosis in various murine disease models (Jeansson et al. 2011 ).
Endothelial Cell-Derived Tumors and Vascular Malformations
A common EC-derived tumor is infantile hemangioma, in which rapidly proliferating endothelial cells give rise to a vascular lesion that can vary from small and innocuous to large and deforming. However, infantile hemangiomas regress spontaneously within several years and treatment is reserved for cases of significant cosmetic and functional interference and complications (North et al. 2006) . Although their pathogenesis is still poorly understood, local dysregulation of angiogenesis involving hypoxia-mediated changes in VEGF and VEGFR expression seem to have an important etiological role in hemangiomas (Kleinman et al. 2007; Przewratil et al. 2010) . Lymphangiomas, on the other hand, are vascular malformations involving lymphatic vessels, and they seem to be exclusively sporadic unlike capillary and venous malformations, which exist in both sporadic and hereditary forms (Brouillard and Vikkula 2007) .
Mutations that increase the ligand-independent autophosphorylation of Tie2 have been identified as an important cause of inherited cutaneomucosal venous malformations, whereas somatic mutations cause more common sporadic lesions (Vikkula et al. 1996; Limaye et al. 2009 ). Contrary to epithelial cell-derived tumors (carcinomas), endothelial cell-derived tumors are mostly benign and the pathogenesis of their rare malignant counterparts (hemangiosarcoma or lymphangiosarcoma) is unclear. Interestingly, such tumors occur as a complication of postmastectomy edema (Janse et al. 1995 ). Kaposi's sarcoma is a more frequent tumor that is thought to arise from human herpesvirus-8-induced reprogramming of lymphatic ECs (Liu et al. 2010 ).
ANTIANGIOGENIC THERAPIES Inhibitors Targeting the VEGF Signaling Pathways
Up-regulation of certain VEGF family members and their receptors has been implicated in the pathogenesis of the majority of human tumors. Blocking antibodies against VEGF-A have shown the clinical utility of VEGF targeting in antiangiogenic tumor therapy (Hurwitz et al. 2004) . Tumor growth inhibition has also been demonstrated with small molecule inhibitors of VEGFRs, anti-VEGFR antibodies, and soluble VEGF-A decoy receptors. However, despite a clear tumor control benefit in clinical trials the response to antiangiogenic therapy is often limited, and relapse of the disease follows (Sennino and McDonald 2012; Singh and Ferrara 2012) . In such cases simultaneous targeting of multiple angiogenic pathways may provide improved therapeutic efficacy in the future. Table 1 lists antiangiogenic drugs in clinical use, or in clinical trials targeting VEGFs, VEGFRs, and angiopoietins, and Figure 3 shows a schematic view of the drugs and the drug targets.
Small Molecule VEGFR Tyrosine Kinase Inhibitors
Small molecule receptor tyrosine kinase inhibitors (TKIs) are typically ATP analogs with limited specificity. A number of small molecule inhibitors, including sorafenib, sunitinib, and pazopanib, have been described that inhibit the intrinsic tyrosine kinase activity of VEGFRs (Bhargava and Robinson 2011) . However, these multitargeted agents inhibit a wide range of kinases in addition to the VEGFRs, and they are associated with adverse effects, some of which may be unrelated to efficient blocking of VEGF signaling. More selective, second-generation VEGFR TKIs tivozanib, axitinib, and cediranib are currently under evaluation. Extensive preclinical and clinical studies using VEGFR TKIs have shown that these second-generation VEGFR TKIs are capable of slowing the growth of primary tumors while having reduced off-target toxicities (Bhargava and Robinson 2011) .
VEGFR Ligand Inhibitors
Targeting the VEGF axis for antiangiogenic tumor therapy was initially demonstrated by using a monoclonal antibody specific for VEGF-A, which inhibited the tumor growth by decreasing the density of tumor blood vessels (Kim et al. 1993 ). Subsequently, the humanized anti-VEGF-A antibody bevacizumab was developed as the first antiangiogenic agent approved for clinical use in combination with chemotherapy for the treatment of metastatic colorectal cancer (Hurwitz et al. 2004; Ferrara et al. 2005) . Ranibizumab, a recombinant humanized monoclonal antibody Fab fragment against VEGF-A, derived from bevacizumab, is being used for the treatment of age-related macular degeneration (AMD) (Rosenfeld et al. 2006) . Antibodies against PlGF have been tested in preclinical models, but the results are controversial concerning the role of PlGF in tumor growth control (Bais et al. 2010; Van de Veire et al. 2010; Snuderl et al. 2013) . Antibodies blocking VEGF-C have shown tumor growth inhibition in preclinical models and VEGF-C-blocking an- Hudkins et al. 2012 tibodies are currently being tested in phase-I clinical trials (VGX-100) (Goyal et al. 2012) . Soluble decoy receptors represent a complementary way to block VEGF signaling pathways by preventing the ligands from binding to their cell-surface receptors. One decoy receptor with a high affinity for VEGF-A is a fusion of the VEGFR-1 ligand-binding domains to an Ig constant region, Flt(1-3)-IgG (Gerber et al. 2000) . Also, a VEGFR-1/VEGFR-2 fusion protein, VEGF-A-Trap, was described as a potent anti-VEGF-A suppressor of tumor growth and vascularization in vivo (Holash et al. 2002) . In recent comparisons of VEGF-A inhibitors, VEGF-A-Trap and Flt(1-3)-IgG had very similar potencies in the bioassays tested and they were both over 10-fold more potent than bevacizumab (Yu et al. 2011; Papadopoulos et al. 2012) . In 2011, VEGF-A-Trap received FDA approval for the treatment of wet AMD and recently also for the treatment of oxaliplatinrefractory metastatic colorectal cancer (see www. fda.gov/Drugs/InformationOnDrugs/Approv edDrugs).
Results of studies using mouse tumor models have suggested that the inhibition of tumorderived VEGF-C with antibodies or a soluble VEGFR-3 decoy receptor represents another possible strategy for blocking of lymphatic metastasis (Lin et al. 2005) . A soluble VEGFR-2 RNA splice variant has also been described as a VEGF-C-specific endogenous inhibitor of lymphatic vessels (Albuquerque et al. 2009 ).
VEGF Receptor-Blocking Antibodies VEGFR activation requires ligand binding and dimerization. In principle, VEGFR activation and signaling can be inhibited either by blocking the ligand-binding site or by blocking receptor dimerization. Current VEGFR-2-and VEGFR-3-blocking antibodies under clinical trials are potent inhibitors of ligand binding (Lu et al. 2003; Persaud et al. 2004) . In theory, targeting VEGF receptors (which have multiple ligands) should be superior to blocking a single ligand. Receptor-blocking antibodies need to compete with the ligand for binding to the VEGFR. This is less of a problem with receptor-blocking antibodies that prevent receptor dimerization (Tvorogov et al. 2010; Kendrew et al. 2011; Hyde et al. 2012) , and some of these may also promote incremental inhibition in combination with antibodies targeted against the VEGFR ligand-binding site. Recent results have furthermore indicated that simultaneous VEGFR-2 and VEGFR-3 inhibition results in additive inhibition of tumor angiogenesis (Tammela et al. 2008) . Neuropilin coreceptors have been suggested as additional targets for tumor therapy (Caunt et al. 2008 ).
Targeting Angiopoietin Signaling
Because of its intricate and context-dependent mechanism of action, the Tie-Ang axis has only recently become a target of antiangiogenic drug development. Tumor and stromal cells express Ang1, whereas Ang2 is predominantly produced by activated ECs ). Ang2 is readily induced in ECs of tumor co-opted blood vessels (Holash et al. 1999) , and in the absence of VEGF-A, Ang2 induces endothelial destabilization and vessel regression, leading to an avascular tumor that is highly hypoxic. This results in increased expression of both Ang2 and VEGF-A, which promote the angiogenic switch in the tumor. Interestingly, one recent study showed that low Ang2 expression levels in the tumor stroma of metastatic colorectal cancer patients were associated with better response rates to VEGFblocking antibodies combined with chemotherapy (Goede et al. 2010) .
A number of studies carried out in various preclinical murine models have shown that blocking Ang2 or both Ang1 and Ang2 significantly inhibits tumor growth and angiogenesis (for original articles, see Saharinen et al. 2011) . Blocking Ang2 resulted in normalized tumor vessels with increased levels of adhesion molecules in EC -EC junctions, increased pericyte coverage, and reduced EC sprouting and vascular remodeling, resulting in smaller, more uniform vessels (Falcon et al. 2009 ). In line with these results, tumors grown in Ang2 2/2 mice displayed a more mature vascular phenotype with increased numbers of pericytes and a smaller vessel diameter than tumors in wild-type mice (Nasarre et al. 2009 ). In addition, Ang2 overexpression induced a switch of the vascular phenotype of a breast cancer xenograft by inducing intratumoral hemorrhages and nonfunctional and abnormal blood vessels with increased EC apoptosis and decreased PC coverage (Reiss et al. 2009 ). At least one study suggests that in combination with Ang2 inhibition, Ang1-blocking agents may prevent tumor vessel normalization (Falcon et al. 2009 ). Accordingly, COMP-Ang1, a recombinant Ang1 protein, induced vessel normalization and improved vessel perfusion and thereby potentiated the effects of chemotherapy in a Lewis lung carcinoma isograft model (Hwang et al. 2009 ). The tumor vessel normalization that occurs during VEGF-A blockage may also be mediated in part by Ang1 (Winkler et al. 2004) .
In addition to its autocrine functions in the ECs, Ang2 modulates the proangiogenic properties of TEMs, which have been shown to contribute to tumor progression (Mazzieri et al. 2011) . Thus, the protumorigenic and proangiogenic functions of Ang2 may involve multiple mechanisms.
Although agents that block the VEGF-A pathway were recently reported to induce invasive growth of some tumors in mice (Ebos et al. 2009; Pàez-Ribes et al. 2009 ), no such effects have been observed in studies testing Ang2-blocking antibodies. In contrast, Ang2-blocking antibodies inhibited the metastatic colonization of the lungs by tumor cells in mouse models, and subsequent metastatic growth (Mazzieri et al. 2011; Holopainen et al. 2012) . The former was at least partially due to enhanced endothelial integrity and improved cell -cell junctions of pulmonary capillaries in Ang2-blocking antibody-treated mice (Holopainen et al. 2012) .
The combination of Ang2 inhibition with cytotoxic drugs, or agents targeting the VEGF-A pathway has shown significantly enhanced efficacy when compared to monotherapy (Brown et al. 2010; Hashizume et al. 2010; Huang et al. 2011; Daly et al. 2013 ). Interestingly, Ang2 overexpression in a mouse model of glioma inhibited the beneficial effects of anti-VEGFR-2 treatment on tumor vessel normalization, brain edema, and animal survival by increasing vascular permeability (Chae et al. 2010 ). This suggests that high Ang2 levels may compromise the efficacy of anti-VEGF-A therapy and that combinatorial inhibition of Ang2 and VEGF-A signaling should be further investigated. To this end, a chimeric decoy receptor, DAAP (double antiangiogenic protein), simultaneously capable of blocking mouse VEGF-A and angiopoietins, was shown to induce regression of tumor vessels, inhibition of metastasis, reduced ascites formation, and vascular leakage (Koh et al. 2010) .
Other specific angiopoietin neutralizing agents that have been used in preclinical models include the soluble Tie2 ectodomain fused to the Fc domain of human immunoglobulin, which binds both Ang1 and Ang2 ligands (Lin et al. 1998) , and an Ang2-specific aptamer (Sarraf-Yazdi et al. 2008 ); however, their clinical applicability is not yet clear.
Currently, several agents targeting the AngTie pathway are in clinical trials (see www. clinicaltrials.gov). A randomized, placebo-controlled phase-II trial showed that an Ang1 and Ang2 dual-specific peptibody (AMG 386) in combination with chemotherapy increased progression-free survival of patients with ovarian cancer (Karlan et al. 2012) . The toxicity profile of AMG 386 was mild and distinct from that of VEGF-A inhibitors. Other Ang2-blocking agents, including a fully human anti-Ang2 monoclonal antibody MEDI 3617 (Leow et al. 2012 ), are currently being tested for safety, dose escalation, and efficacy in phase I/II clinical trials. CEP-11981, a Tie2 and VEGFR tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities, is also being tested in clinical phase-I trials, but no information about its potential in tumor growth inhibition is yet available (Hudkins et al. 2012) .
CONCLUSIONS
The endothelial cell-specific RTKs are the central effector molecules that orchestrate the development of the vasculature. Because of its omnipresence the vasculature is intimately involved in and affected by many disease processes. VEGF and Tie receptors have gathered most of the attention due to their central roles in tumor growth and progression. Detailed knowledge of these receptors and their functions has allowed the development of additional therapeutic agents against cancer and other diseases where angiogenesis is a contributor. Several drugs have been approved for the treatment of human cancers and certain eye diseases. However, the current data suggest that the existing drugs do not max out the possibilities of antiangiogenic therapy in cancer. Therefore, improved ("secondgeneration") antiangiogenic drugs are in development. On the flip side, the development of proangiogenic therapies, which could be beneficial in a variety of diseases characterized by insufficient angiogenesis, has not progressed to routine clinical applications. Because proand antiangiogenic therapies aim at antagonistic goals, there might be intrinsic limits to their applicability. Would the proangiogenic therapy of coronary heart disease increase the incidence of some types of tumors? Or would long-term antiangiogenic tumor therapy (e.g., to prevent reoccurrence) compromise the vascular health in a patient? To answer these questions we will have to learn more about the molecular basis of vascular biology and this knowledge in turn will allow at least incremental improvements of the existing therapeutic strategies as well as the design of new ones.
